van Eekelen, Leander
Spronck, Joey
Looijen-Salamon, Monika
Vos, Shoko
Munari, Enrico
Girolami, Ilaria
Eccher, Albino
Acs, Balazs
Boyaci, Ceren
de Souza, Gabriel Silva
Demirel-Andishmand, Muradije
Meesters, Luca Dulce
Zegers, Daan
van der Woude, Lieke
Theelen, Willemijn
van den Heuvel, Michel
Grünberg, Katrien
van Ginneken, Bram
van der Laak, Jeroen
Ciompi, Francesco
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (18388)
Article History
Received: 17 November 2023
Accepted: 14 March 2024
First Online: 26 March 2024
Competing interests
: IG is a member of the advisory board for Roche Diagnostics. WT reports research funding from Astrazeneca, MSD and Sanofi/Regeneron. MvdH reports sponsorship or research funding from Amgen, Astrazeneca, BMS, Janssen Pharmaceutica, Stichting Treatmeds, Merck, MSD, Novartis, Pamgene, Pfizer, Roche and Roche diagnostics. BvG is a shareholder of Thirona BV, the Netherlands. JvdL was a member of the advisory boards of Philips, the Netherlands and ContextVision, Sweden, and received research funding from Philips, the Netherlands, ContextVision, Sweden, and Sectra, Sweden in the last five years. He is chief scientific officer (CSO) and shareholder of Aiosyn BV, the Netherlands. FC was chair of the Scientific and Medical Advisory Board of TRIBVN Healthcare, France, and received advisory board fees from TRIBVN Healthcare, France in the last five years. He is a shareholder of Aiosyn BV, the Netherlands. All other authors declare no potential conflict of interest.